Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A century of yellow fever research].

MMW Fortschritte der Medizin·2026
Same author

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease.

International journal of molecular sciences·2026
Same author

The <i>GBA1</i> p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

medRxiv : the preprint server for health sciences·2026
Same author

Reply to: "Unravelling the Complexity of VPS16 Splicing: Clinical Implications and Unresolved Questions".

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Genotypes truncating the intracellular tail of human pre-TCRα: From amorphic to isomorphic.

Journal of human immunity·2026

Related Experiment Video

Updated: Dec 15, 2025

Large-Scale SARS-CoV-2 Testing Utilizing Saliva and Transposition Sample Pooling
08:26

Large-Scale SARS-CoV-2 Testing Utilizing Saliva and Transposition Sample Pooling

Published on: June 23, 2022

1.9K

Rapid Large-Scale COVID-19 Testing During Shortages.

Christian Beetz1, Volha Skrahina1, Toni M Förster1

  • 1CENTOGENE AG, 18055 Rostock, Germany.

Diagnostics (Basel, Switzerland)
|July 12, 2020
PubMed
Summary
This summary is machine-generated.

A new SARS-CoV-2 testing platform was developed to overcome shortages and ensure early COVID-19 detection. This flexible system enabled large-scale testing, supporting critical infrastructure and providing a blueprint for future pandemic responses.

Keywords:
COVID-19RT-PCRSARS-CoV-2preventive testingtestingvalidation

More Related Videos

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.4K
Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots
11:11

Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots

Published on: February 11, 2022

4.9K

Related Experiment Videos

Last Updated: Dec 15, 2025

Large-Scale SARS-CoV-2 Testing Utilizing Saliva and Transposition Sample Pooling
08:26

Large-Scale SARS-CoV-2 Testing Utilizing Saliva and Transposition Sample Pooling

Published on: June 23, 2022

1.9K
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.4K
Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots
11:11

Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots

Published on: February 11, 2022

4.9K

Area of Science:

  • Virology
  • Public Health
  • Biotechnology

Background:

  • The COVID-19 pandemic necessitates rapid and reliable SARS-CoV-2 testing for control.
  • Challenges include reagent shortages and secure reporting, hindering large-scale testing efforts.

Purpose of the Study:

  • To establish a holistic and flexible SARS-CoV-2 testing platform.
  • To validate the platform's performance and demonstrate its utility in a real-world setting.

Main Methods:

  • Development of a comprehensive platform: registration, sample collection, RT-PCR testing, and report issuing.
  • Validation of RT-PCR assay (96.8% sensitivity, 100% specificity) and novel sample collection/RNA extraction tools.
  • Application of the platform for large-scale testing in north-eastern Germany.

Main Results:

  • Successfully implemented a SARS-CoV-2 testing platform, overcoming supply chain bottlenecks.
  • Tested nearly 10,000 individuals, identifying five positive cases with diverse viral origins.
  • Enabled safe operation of critical infrastructure, including nursing homes.

Conclusions:

  • The developed platform offers a rapid, flexible, and validated approach to large-scale SARS-CoV-2 testing.
  • This strategy can serve as a model for implementing preventive testing in diverse settings.
  • The platform ensures independence from supply chain issues, crucial for pandemic management.